Treatment options for DLBCL patients who relapse after CAR-T cell therapy

In this video, Enrico Derenzini, MD, PhD, European Institute of Oncology, Milan, Italy, highlights the important role of bispecific antibodies as a treatment option for patients with diffuse large B-cell lymphoma (DLBCL) who relapse after CD19 CAR-T therapy, and further discusses pre-clinical trials in this space. This interview took place at the 4th Society of Hematologic Oncology (SOHO) Italy Annual Conference, held in Rome, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.